Skip to main content

Advertisement

Table 1 Demographic data from identified studies in the literature and our cases a

From: Breast cancer arising within fibroadenoma: collective analysis of case reports in the literature and hints on treatment policy

Patient Study Age (yr) Tumor size (cm) Noted tumor duration (months) Histology TNM stage Surgery LN dissection LN metastasis Receptor status C/T H/T R/T Outcome
1 Kurosumi et al., 1994[14] 42 2 × 3 21 IDC   Ex A       
2 Sarela et al., 1995[15] 56 2 × 3 2 LCIS + IDC   MT A P      
3 Shah et al., 1999[16] 45 2.5 × 2 3 LCIS TisN0M0 Ex   N      
4 Yano et al., 2001[17] 54 2   ILC TisN0M0 Ex A N      
5 Kuijper et al., 2002[18] 46 Multiple   DCIS + LCIS TisN0M0 MT        
6 Abe et al., 2004[19] 42 5.1 × 4.4 60 IDC   MT A P ER-PR+ Yes Yes No  
7 Stafyla et al., 2004[20] 27 3.4   LCIS TisN0M0 Ex   N      
8 Shin et al., 2006[21] 51 1.5 × 1 12 IDC   MT S N ER+PR+     
9 Yuen et al., 2007[22] 39 1.1   ILC   BCS        
10 Yuen et al., 2007[22] 45 0.8   ILC   BCS        
11 Borecky and Rickard, 2008[23] 64 1.2   IDC T1bN0M0 BCS S N ER+PR+     
12 Borecky and Rickard, 2008[23] 80 4.5 600 IDC   BCS S N      
13 Borecky and Rickard, 2008[23] 53 1.7 12 DCIS TisN0M0 Ex S N      
14 Gashi-Luci et al., 2009[24] 39 2.6 × 1.6   IDC   MT A N ER-PR-     R
           HER2-     
15 Khandelwal et al., 2009[25] 35 2 × 3 2 IDC   BCS A P ER+PR+ Yes Yes Yes  
           HER2-     
16 Iyengar et al., 2009[26] 43 1.8 24 IDC   MT    ER-PR-     
           HER2+     
17 Rao et al., 2010[27] 30 4 × 2 1 IDC   MT A P ER-PR- Yes No Yes  
           HER2-     
18 Petersson et al., 2010[28] 49 3 48 IDC   Ex S N ER+PR+     
           HER2-     
19 Kato et al., 2011[29] 42 1.5   DCIS TisN0M0 BCS S N      
20 Ooe et al., 2011[30] 46 2.4 × 1.7 60 DCIS TisN0M0 BCS S N ER+PR+ No Yes Yes  
21 Tajima et al., 2011[31] 60 1.9 × 1.6 3 ILC   BCS    ER+PR+     
           HER2-     
22 Abu-Rahmeh et al., 2012[32] 69 5 180 IDC          Lung metastasisb
23 Jahan et al., 2012[33] 55 5 × 4 × 3 240 IDC   MT        
24 Butler et al., 2012[34] 46 0.8 × 0.8   ILC T1bN0M0 Ex        
25 Present study 39 2.7 × 2.7 24 IDC T1aN0M0 BCS S N ER+PR+ No Nr Nr  
           HER2-     
26 Present study 31 3.5 × 3.4 84 IDC T1aN1M0 MT A P ER+PR+ Yes Yes No  
           HER2-     
27 Present study 30 1.5 × 1.4   DCIS TisN0M0 BCS    ER+PR+ No Yes No  
           HER2-     
28 Present study 63 1.2 0.5 DCIS TisN0M0 BCS S N ER+PR+ No Yes Yes  
           HER2-     
29 Present study 48 0.9 3 DCIS TisN0M0 Ex S N   No No No  
30 Present study 40 0.6 0 IDC T1bN0M0 MT S N ER +PR- No Yes No  
  1. aA, Axillary lymph node dissection level I/II/III; B, Benign; C/T, Chemotherapy; ER, Estrogen receptor; Ex, Excision; HER2, Human epidermal growth factor receptor 2 ; H/T, Hormone therapy; LN, Lymph node; M, Malignancy; MT, Mastectomy; N, Negative; Nr, Patient refuse; P, Positive; PR, Progesterone receptor; R, Recurrence; R/T, Radiotherapy; S, Sentinel lymph node dissection; TNM, Tumor, node, metastasis. bLung metastasis at diagnosis.